The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
[OPTIMAL 3] A phase III trial to evaluate the efficacy and safety of DHP107 (Liporaxel, oral paclitaxel) compared to Taxol (IV paclitaxel) as first line therapy in patients with recurrent or metastatic HER2 negative breast cancer (BC) (NCT03315364).
 
Sung-Bae Kim
Honoraria - DAEHWA Pharmaceutical; Enzychem Lifesciences; ISU ABXIS
Consulting or Advisory Role - AstraZeneca; DAEHWA Pharmaceutical; Enzychem Lifesciences (Inst); ISU Abxis; Lilly (Inst)
Research Funding - Dongkook Pharma (Inst); Genzyme (Inst); Kyowha Kirin (Inst); Novartis (Inst)
 
Qingyuan Zhang
No Relationships to Disclose
 
Tao Sun
No Relationships to Disclose
 
Jae Hong Seo
No Relationships to Disclose
 
Keun Seok Lee
No Relationships to Disclose
 
Tae-Yong Kim
No Relationships to Disclose
 
Zhongsheng Tong
No Relationships to Disclose
 
Kyong Hwa Park
No Relationships to Disclose
 
Yong Wha Moon
No Relationships to Disclose
 
Shusen Wang
No Relationships to Disclose
 
Wei Li
No Relationships to Disclose
 
Yaewon Yang
No Relationships to Disclose
 
Jingfen Wang
No Relationships to Disclose
 
Xian Wang
No Relationships to Disclose
 
Jonggwon Choi
No Relationships to Disclose
 
Ji Eun Lee
No Relationships to Disclose
 
Koung Eun Yoon
Employment - DAEHWA Pharmaceutical
 
Seongwuen Chung
Employment - DAEHWA Pharmaceutical
 
Binghe Xu
Speakers' Bureau - AstraZeneca; Eisai; Pfizer; Roche
Research Funding - Jiangsu Hengrui Medicine (Inst)
 
Joohyuk Sohn
Research Funding - AstraZeneca (Inst); Bayer (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)